Published in Eur Radiol on December 13, 2016
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed (2000) 8.18
Simultaneous in vivo spectral editing and water suppression. NMR Biomed (1998) 5.09
Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage (2003) 2.52
GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci (2010) 2.49
1H MR spectroscopy in common dementias. Neurology (2004) 2.39
Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn Reson Med (2009) 1.99
Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging (2007) 1.64
Magnetic resonance spectroscopy in AD. Neurology (2001) 1.59
Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology (1993) 1.58
Gannet: A batch-processing tool for the quantitative analysis of gamma-aminobutyric acid–edited MR spectroscopy spectra. J Magn Reson Imaging (2013) 1.57
Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport (1991) 1.52
A proton magnetic resonance spectroscopy study of age-related changes in frontal lobe metabolite concentrations. Cereb Cortex (2001) 1.38
Reduced GABA concentration in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry (2012) 1.35
Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol (1994) 1.31
Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J Magn Reson Imaging (1999) 1.27
MR spectroscopy in neurodegenerative disease. Mol Imaging Biol (2007) 1.17
Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry (2000) 1.16
Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging (2009) 1.12
Effects of age and sex on brain glutamate and other metabolites. Magn Reson Imaging (2008) 1.10
Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage (2013) 1.06
Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. Dement Geriatr Cogn Disord (2005) 1.04
Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis (2010) 1.03
Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain (2002) 1.02
Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen (2011) 1.00
The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging (1993) 0.98
Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging (2007) 0.96
Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci Lett (2003) 0.92
Alzheimer's disease-related synapse loss in the cingulate cortex. J Alzheimers Dis (2001) 0.89
Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease. Neuropharmacology (2013) 0.88
In vivo detection of acute pain-induced changes of GABA+ and Glx in the human brain by using functional 1H MEGA-PRESS MR spectroscopy. Neuroimage (2014) 0.87
Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study. J Neurochem (2012) 0.85
Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord (2010) 0.83
Age-related changes in the uptake and release of glutamate and aspartate in the mouse brain. Mech Ageing Dev (1995) 0.79
Physiological neuronal decline in healthy aging human brain - An in vivo study with MRI and short echo-time whole-brain (1)H MR spectroscopic imaging. Neuroimage (2016) 0.75